- Home
- AGL vs CDIO Comparison
AGL vs CDIO Comparison
Compare AGL & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | CDIO |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Managed Health Care | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGL | CDIO |
|---|---|---|
| Price | $80.72 | $1.43 |
| Analyst Decision | Hold | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $55.68 | N/A |
| AVG Volume (30 Days) | ★ 555.5K | 63.6K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $5,932,576,000.00 | N/A |
| Revenue This Year | N/A | $171,906.75 |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $30.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.97 |
| 52 Week High | $90.48 | $7.91 |
Technical Indicators
Market Signals| Indicator | AGL | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 78.35 | 32.67 |
| Support Level | $0.63 | $1.18 |
| Resistance Level | N/A | $2.13 |
| Average True Range (ATR) | 8.71 | 0.19 |
| MACD | 3.52 | -0.02 |
| Stochastic Oscillator | 87.14 | 16.36 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
About CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.